KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $54.4 million.

  • Amneal Pharmaceuticals' Change in Account Payables fell 120.39% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 43.05%. This contributed to the annual value of $54.4 million for FY2024, which is 453.88% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Change in Account Payables stood at $54.4 million for FY2024, which was up 453.88% from $9.8 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Account Payables peaked at $54.4 million during FY2024, and registered a low of -$2.4 million during FY2021.
  • Moreover, its 3-year median value for Change in Account Payables was $9.8 million (2023), whereas its average is $22.1 million.
  • In the last 5 years, Amneal Pharmaceuticals' Change in Account Payables plummeted by 243.07% in 2021 and then soared by 453.88% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Change in Account Payables stood at $1.6 million in 2020, then tumbled by 243.07% to -$2.4 million in 2021, then spiked by 187.98% to $2.1 million in 2022, then skyrocketed by 374.37% to $9.8 million in 2023, then skyrocketed by 453.88% to $54.4 million in 2024.